Dutch Competition Body Urged To Fine Leadiant Over 'Exorbitant' Orphan Drug Price
The Dutch Pharmaceutical Accountability Foundation has asked the country's competition authority to take action against Leadiant Biosciences over the company's pricing of an orphan drug for a rare genetic disease.
You may also be interested in...
Medicines prepared in pharmacies are now exempt from patent law in the Netherlands, giving pharmacists greater scope to prepare their own versions of patented medicines.
AstraZeneca is being pursued in court for compensation over what a health insurer calls the “unnecessarily high price” that the company charged for Seroquel.
A new Dutch foundation set up to address cases of what it says are excessive drug pricing says it plans to refer Leadiant Biosciences’ CDCA product for the rare genetic disease, cerebrotendinous xanthomatosis, to the competition authorities.